The U.S. Prostate-Specific Antigen Test Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 6.1% to reach USD 2.7 billion by 2035.
Market growth is driven by increasing emphasis on early-stage cancer detection, continuous advancements in PSA assay technologies, and a rising incidence of prostate cancer across the country. Greater awareness among patients and healthcare providers regarding the benefits of routine screening is significantly supporting demand for PSA testing. Improvements in diagnostic accuracy through advancements in biomarker science and enhanced assay sensitivity are strengthening clinical confidence in these tests. In addition, favorable reimbursement policies are improving accessibility and encouraging widespread adoption across healthcare systems. Strategic collaborations between biotechnology firms and diagnostic laboratories are also contributing to innovation and expanding testing capabilities. The growing aging male population, combined with the increasing integration of PSA testing into preventive healthcare practices, is further driving market expansion. As healthcare systems continue to prioritize early detection and precision diagnostics, the demand for reliable, efficient, and accessible PSA testing solutions is expected to rise steadily across the United States.
The preliminary testing segment accounted for a 73.4% share in 2025. This segment plays a critical role as the initial step in prostate cancer evaluation, offering healthcare providers efficient and minimally invasive tools for early risk assessment. Routine screening recommendations and increased clinical adoption are driving sustained growth in this segment. Blood-based PSA testing methods remain widely utilized in general health checkups and primary care environments, contributing to high testing volumes. Their ability to provide quick and reliable insights into potential health concerns makes them an essential component of early diagnostic pathways.
The prostate cancer screening segment generated USD 908.7 million in 2025. This application area represents a key pillar of the U.S. prostate-specific antigen testing market, as it supports early identification of prostate cancer and enables timely clinical intervention. Increased focus on preventive healthcare and improved patient outcomes is reinforcing the importance of screening programs. Expanding awareness campaigns and healthcare initiatives are also encouraging more individuals to undergo regular screening, thereby strengthening demand across this segment.
Leading companies operating in the U.S. Prostate-Specific Antigen Test Market include Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, F. Hoffmann La Roche Ltd., Koninklijke Philips N.V., GE HealthCare Technologies Inc., Quest Diagnostics, LabCorp Holdings Inc., Myriad Genetics, Inc., OPKO Health, Inc., Veracyte, Inc., Cleveland Diagnostics, Inc., MDxHealth SA, Glycanostics, s.r.o., Koelis SAS, CTK Biotech, Inc. (SSI Diagnostica Group), and Advacare Pharma. These organizations are actively engaged in advancing diagnostic technologies and expanding their market presence through innovation and strategic collaborations. Companies in the U.S. Prostate-Specific Antigen Test Market are adopting a range of strategies to strengthen their competitive positioning and expand their footprint. A primary focus is on advancing diagnostic accuracy through the development of next-generation biomarker-based assays and multi-marker testing platforms. Firms are investing heavily in research and development to enhance sensitivity, reduce false positives, and improve clinical outcomes. Strategic partnerships with hospitals, diagnostic laboratories, and research institutions are enabling broader access and faster commercialization of new technologies. Companies are also expanding their service offerings through integrated diagnostic solutions and digital health platforms. In addition, efforts to secure regulatory approvals and expand reimbursement coverage are improving market accessibility.
This product will be delivered within 2-4 business days.
Market growth is driven by increasing emphasis on early-stage cancer detection, continuous advancements in PSA assay technologies, and a rising incidence of prostate cancer across the country. Greater awareness among patients and healthcare providers regarding the benefits of routine screening is significantly supporting demand for PSA testing. Improvements in diagnostic accuracy through advancements in biomarker science and enhanced assay sensitivity are strengthening clinical confidence in these tests. In addition, favorable reimbursement policies are improving accessibility and encouraging widespread adoption across healthcare systems. Strategic collaborations between biotechnology firms and diagnostic laboratories are also contributing to innovation and expanding testing capabilities. The growing aging male population, combined with the increasing integration of PSA testing into preventive healthcare practices, is further driving market expansion. As healthcare systems continue to prioritize early detection and precision diagnostics, the demand for reliable, efficient, and accessible PSA testing solutions is expected to rise steadily across the United States.
The preliminary testing segment accounted for a 73.4% share in 2025. This segment plays a critical role as the initial step in prostate cancer evaluation, offering healthcare providers efficient and minimally invasive tools for early risk assessment. Routine screening recommendations and increased clinical adoption are driving sustained growth in this segment. Blood-based PSA testing methods remain widely utilized in general health checkups and primary care environments, contributing to high testing volumes. Their ability to provide quick and reliable insights into potential health concerns makes them an essential component of early diagnostic pathways.
The prostate cancer screening segment generated USD 908.7 million in 2025. This application area represents a key pillar of the U.S. prostate-specific antigen testing market, as it supports early identification of prostate cancer and enables timely clinical intervention. Increased focus on preventive healthcare and improved patient outcomes is reinforcing the importance of screening programs. Expanding awareness campaigns and healthcare initiatives are also encouraging more individuals to undergo regular screening, thereby strengthening demand across this segment.
Leading companies operating in the U.S. Prostate-Specific Antigen Test Market include Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, F. Hoffmann La Roche Ltd., Koninklijke Philips N.V., GE HealthCare Technologies Inc., Quest Diagnostics, LabCorp Holdings Inc., Myriad Genetics, Inc., OPKO Health, Inc., Veracyte, Inc., Cleveland Diagnostics, Inc., MDxHealth SA, Glycanostics, s.r.o., Koelis SAS, CTK Biotech, Inc. (SSI Diagnostica Group), and Advacare Pharma. These organizations are actively engaged in advancing diagnostic technologies and expanding their market presence through innovation and strategic collaborations. Companies in the U.S. Prostate-Specific Antigen Test Market are adopting a range of strategies to strengthen their competitive positioning and expand their footprint. A primary focus is on advancing diagnostic accuracy through the development of next-generation biomarker-based assays and multi-marker testing platforms. Firms are investing heavily in research and development to enhance sensitivity, reduce false positives, and improve clinical outcomes. Strategic partnerships with hospitals, diagnostic laboratories, and research institutions are enabling broader access and faster commercialization of new technologies. Companies are also expanding their service offerings through integrated diagnostic solutions and digital health platforms. In addition, efforts to secure regulatory approvals and expand reimbursement coverage are improving market accessibility.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies profiled in this U.S. Prostate-Specific Antigen Test market report include:- Abbott Laboratories
- Advacare Pharma
- Cleveland Diagnostics, Inc.
- CTK Biotech, Inc. (SSI Diagnostica Group)
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- GE HealthCare Technologies Inc.
- Glycanostics, s.r.o.
- Koelis SAS
- Koninklijke Philips N.V.
- LabCorp Holdings Inc.
- MDxHealth SA
- Myriad Genetics, Inc.
- OPKO Health, Inc.
- Quest Diagnostics
- Siemens Healthineers AG
- Veracyte, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | April 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 2.7 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 18 |
